keyword
MENU ▼
Read by QxMD icon Read
search

Pasireotide

keyword
https://www.readbyqxmd.com/read/28050766/selective-perioperative-administration-of-pasireotide-is-more-cost-effective-than-routine-administration-for-pancreatic-fistula-prophylaxis
#1
Jason W Denbo, Rebecca S Slack, Morgan Bruno, Jordan M Cloyd, Laura Prakash, Jason B Fleming, Michael P Kim, Thomas A Aloia, Jean-Nicolas Vauthey, Jeffrey E Lee, Matthew H G Katz
BACKGROUND: In a randomized trial, pasireotide significantly decreased the incidence and severity of postoperative pancreatic fistula (POPF). Subsequent analyses concluded that its routine use is cost-effective. We hypothesized that selective administration of the drug to patients at high risk for POPF would be more cost-effective. STUDY DESIGN: Consecutive patients who did not receive pasireotide and underwent pancreatoduodenectomy (PD) or distal pancreatectomy (DP) between July 2011 and January 2014 were distributed into groups based on their risk of POPF using a multivariate recursive partitioning regression tree analysis (RPA) of preoperative clinical factors...
January 3, 2017: Journal of Gastrointestinal Surgery: Official Journal of the Society for Surgery of the Alimentary Tract
https://www.readbyqxmd.com/read/28045714/how-much-should-we-pay-to-minimize-pancreatic-leak-the-cost-effectiveness-of-pasireotide-in-pancreatic-resection-retracted
#2
Daniel E Abbott, Jeffrey M Sutton, Peter L Jernigan, Alex Chang, Patrick Frye, Shimul A Shah, Daniel P Schauer, Mark H Eckman, Syed A Ahmad, Jeffrey J Sussman
INTRODUCTION: Pasireotide was recently shown to decrease leak rates after pancreatic resection, though the significant cost of the drug may be prohibitive. We conducted a cost-effectiveness analysis to determine whether prophylactic pasireotide possesses a reasonable cost profile by improving outcomes. METHODS: A cost-effectiveness model was constructed to compare pasireotide administration after pancreatic resection versus usual care, populated by probabilities of clinical outcomes from a recent randomized trial and hospital costs (2013 US$) from a university pancreatic disease center...
December 30, 2016: Annals of Surgery
https://www.readbyqxmd.com/read/28008238/communication-practices-and-awareness-of-resources-for-acromegaly-patients-among-endocrinologists
#3
Susan Polanco-Briceno, Daniel Glass, Cindy Plunkett
PURPOSE: This study was designed to assess the awareness and utilization of resources to improve patients' treatment experiences among endocrinologists who currently treat patients with acromegaly. METHODS: A total of 4,280 US endocrinologists were randomly selected from the CMS National Plan and Provider Enumeration System and were invited by mail to participate in a 20-minute online survey. In order to qualify, respondents had to be the primary physician making treatment decisions for at least one patient for their acromegaly...
2016: Patient Preference and Adherence
https://www.readbyqxmd.com/read/27971743/a-cost-effectiveness-analysis-of-pasireotide-long-acting-compared-to-continued-use-of-a-first-line-somatostatin-antagonist-for-the-treatment-of-acromegaly-in-sweden
#4
P Carlqvist, A Wilen-Koort
No abstract text is available yet for this article.
November 2016: Value in Health: the Journal of the International Society for Pharmacoeconomics and Outcomes Research
https://www.readbyqxmd.com/read/27966451/fgfr4-polymorphic-alleles-modulate-mitochondrial-respiration-a-novel-target-for-somatostatin-analog-action-in-pituitary-tumors
#5
Shereen Ezzat, Ri Wang, Melania Pintilie, Sylvia L Asa
We reported that a single nucleotide polymorphism (SNP) at codon 388 of the fibroblast growth factor receptor 4 (FGFR4-Gly388Arg) can result in distinct proteins that alter pituitary cell growth and function. Here, we examined the differential properties of the available therapeutic somatostatin analogs, octreotide and pasireotide, in pituitary tumor cells expressing the different FGFR4 isoforms. Consistent with their enhanced growth properties, FGFR4-R388-expressing cells show higher mitochondrial STAT3 serine phosphorylation driving basal and maximal oxygen consumption rate (OCR) than pituitary cells expressing the more common FGFR4-G388 isoform...
December 9, 2016: Oncotarget
https://www.readbyqxmd.com/read/27900635/somatostatin-and-dopamine-receptor-regulation-of-pituitary-somatotroph-adenomas
#6
REVIEW
Anat Ben-Shlomo, Ning-Ai Liu, Shlomo Melmed
Somatostatin and dopamine receptors are expressed in normal and tumoral somatotroph cells. Upon receptor stimulation, somatostatin and the somatostatin receptor ligands octreotide, lanreotide, and pasireotide, and to a lesser extent, dopamine and the dopamine analogs bromocriptine and cabergoline, suppress growth hormone (GH) secretion from a GH-secreting pituitary somatotroph adenoma. Somatostatin and dopamine receptors are Gαi-protein coupled that inhibit adenylate cyclase activity and cAMP production and reduce intracellular calcium concentration and calcium flux oscillations...
November 29, 2016: Pituitary
https://www.readbyqxmd.com/read/27896545/safety-and-tolerability-of-pasireotide-long-acting-release-in-acromegaly-results-from-the-acromegaly-open-label-multicenter-safety-monitoring-program-for-treating-patients-who-have-a-need-to-receive-medical-therapy-access-study
#7
Maria Fleseriu, Elisha Rusch, Eliza B Geer
PURPOSE: Pasireotide long-acting release is a somatostatin analog that is indicated for treatment of patients with acromegaly. This analysis documents the safety of pasireotide long-acting release in patients with acromegaly enrolled in the ACCESS trial (ClinicalTrials.gov identifier: NCT01995734). METHODS: ACCESS is an open-label, multicenter, single-arm, expanded-treatment protocol designed to provide patients access to pasireotide long-acting release pending regulatory approval...
November 28, 2016: Endocrine
https://www.readbyqxmd.com/read/27894193/currently-used-and-investigational-drugs-for-cushing%C3%A2-s-disease
#8
Denis Ciato, Aizhar G Mumbach, Marcelo Paez-Pereda, Günter K Stalla
Cushing's disease (CD) is caused by a corticotroph adenoma of the pituitary gland that secretes excess adrenocorticotropic hormone (ACTH) causing increased morbidity and mortality. Surgery is the treatment of choice, but is not always successful. Alternatives include radiotherapy, adrenal surgery, and pharmaceutical therapy. The latter is increasingly gaining momentum due to the recent development of compounds that reduce hypercortisolaemia or its symptoms, acting through different mechanisms. Areas covered: In this article, the authors provide a complete overview of the treatment options for Cushing´s disease, including adrenal-directed, tumor-targeted, and peripheral therapies that are currently used or in development, and discuss their potential advantages and limitations...
January 2017: Expert Opinion on Investigational Drugs
https://www.readbyqxmd.com/read/27874965/somatostatin-agonist-pasireotide-inhibits-exercise-stimulated-growth-in-the-male-siberian-hamster-phodopus-sungorus
#9
Rebecca Dumbell, Ines Petri, Frank Scherbarth, Victoria Diedrich, Herbert A Schmid, Stephan Steinlechner, Perry Barrett
The Siberian hamster (Phodopus sungorus) is a seasonal mammal, exhibiting a suite of physiologically and behaviourally distinct traits dependent on the time of year and governed by changes in perceived day length (photoperiod). These attributes include significant weight loss, reduced food intake, gonadal atrophy, and pelage change with short day photoperiod as in winter. The central mechanisms driving seasonal phenotype change during winter are mediated by a reduced availability of hypothalamic tri-iodothyronine (T3), but downstream mechanisms responsible for physiological and behavioural changes are yet to be fully elucidated...
November 22, 2016: Journal of Neuroendocrinology
https://www.readbyqxmd.com/read/27787949/pasireotide-prevents-nuclear-factor-of-activated-t-cells-nuclear-translocation-and-acts-as-a-protective-agent-in-aminoglycoside-induced-auditory-hair-cell-loss
#10
Daniel Bodmer, Adrijana Perkovic, Marijana Sekulic-Jablanovic, Matthew B Wright, Vesna Petkovic
Hearing impairment is a global health problem with a high socioeconomic impact. Damage to auditory hair cells (HCs) in the inner ear as a result of aging, disease, trauma, or toxicity, underlies the majority of cases of sensorineural hearing loss. Previously we demonstrated that the Ca(2+) -sensitive neuropeptide, somatostatin (SST), and an analog, octreotide, protect HCs from gentamicin-induced cell death in vitro. Aminoglycosides such as gentamicin trigger a calcium ion influx (Ca(2+) ) that activates pro-apoptotic signaling cascades in HCs...
December 2016: Journal of Neurochemistry
https://www.readbyqxmd.com/read/27697899/somatostatin-analogues-in-acromegaly-and-gastroenteropancreatic-neuroendocrine-tumours-past-present-and-future
#11
REVIEW
Kjell Öberg, Steven W J Lamberts
Acromegaly is a hormonal disorder that arises when the pituitary gland secretes excess growth hormone (GH), which in turn stimulates a concomitant increase in serum insulin-like growth factor 1 (IGF-1) levels. Gastroenteropancreatic neuroendocrine tumours (GEP-NET) constitute a heterogeneous group of tumours that can secrete serotonin and a variety of peptide hormones that may cause characteristic symptoms known as carcinoid syndrome or other symptoms and hormonal hypersecretion syndromes depending on the tumour's site of origin...
December 2016: Endocrine-related Cancer
https://www.readbyqxmd.com/read/27639583/paradoxical-and-atypical-responses-to-pasireotide-in-aggressive-acth-secreting-pituitary-tumors
#12
Yona Greenman, Naftali Stern
PURPOSE: Pasireotide is the only pituitary targeted medication registered for the treatment of Cushing's disease. Drug efficacy data are largely based on a major prospective study in which the vast majority of patients had microadenomas. The purpose of this study was to summarize results of pasireotide treatment of ACTH secreting macroadenomas from our center. METHODS: Retrospective review of data extracted from clinical files. RESULTS: Three patients presented with large and invasive macroadenomas that required several surgical interventions and radiotherapy treatments...
December 2016: Pituitary
https://www.readbyqxmd.com/read/27635672/treatment-of-symptomatic-neuroendocrine-tumor-syndromes-recent-advances-and-controversies
#13
Tetsuhide Ito, Lingaku Lee, Robert T Jensen
INTRODUCTION: Neuroendocrine tumors(NETs), once thought rare, are increasing in frequency in most countries and receiving increasing-attention. NETs present two-treatment problems. A proportion is aggressive and a proportion has a functional, hormone-excess-state(F-NET) each of which, must be treated. Recently, there have been many advances, well-covered in reviews/consensus papers on imaging-NETs; new, novel anti-tumor treatments and understanding their pathogenesis. However, little attention has been paid to advances in the treatment of the hormone-excess-state...
September 16, 2016: Expert Opinion on Pharmacotherapy
https://www.readbyqxmd.com/read/27628685/perioperative-application-of-somatostatin-analogs-for-pancreatic-surgery-current-status-in-germany
#14
Andreas Volk, Philipp Nitschke, Franziska Johnscher, Nuh Rahbari, Thilo Welsch, Christoph Reißfelder, Jürgen Weitz, Marius Distler, Soeren Torge Mees
BACKGROUND: The most common major complication after pancreatic resection is the postoperative pancreatic fistula (POPF). Somatostatin analogs can reduce POPF, but the use of somatostatin analogs is still controversial. The aim of this study was to assess treatment algorithms for pancreatic surgery in Germany with a special focus on the application of somatostatin analogs. METHODS: A questionnaire evaluating the perioperative management-especially the use of somatostatin analogs-and postoperative complications after pancreatic surgery was developed and sent to 209 German hospitals performing >12 pancreatoduodenectomies per year (the requirement for certification as a pancreas center)...
November 2016: Langenbeck's Archives of Surgery
https://www.readbyqxmd.com/read/27611616/invited-commentary-pasireotide-and-the-prevention-of-pancreatic-fistula-after-pancreatectomy-the-continued-search-for-harry-potter-s-liquid-luck
#15
https://www.readbyqxmd.com/read/27587848/octreotide-and-pasireotide-dis-similarly-inhibit-pituitary-tumor-cells-in-vitro
#16
Alejandro Ibáñez-Costa, Esther Rivero-Cortés, Mari C Vázquez-Borrego, Manuel D Gahete, Luis Jiménez-Reina, Eva Venegas-Moreno, Andrés de la Riva, Miguel Ángel Arráez, Inmaculada González-Molero, Herbert A Schmid, Silvia Maraver-Selfa, Inmaculada Gavilán-Villarejo, Juan Antonio García-Arnés, Miguel A Japón, Alfonso Soto-Moreno, María A Gálvez, Raúl M Luque, Justo P Castaño
Somatostatin analogs (SSA) are the mainstay of pharmacological treatment for pituitary adenomas. However, some patients escape from therapy with octreotide, a somatostatin receptor 2 (sst2)-preferring SSA, and pasireotide, a novel multi-sst-preferring SSA, may help to overcome this problem. It has been proposed that correspondence between sst1-sst5 expression pattern and SSA-binding profile could predict patient's response. To explore the cellular/molecular features associated with octreotide/pasireotide response, we performed a parallel comparison of their in vitro effects, evaluating sst1-sst5 expression, intracellular Ca(2+) signaling ([Ca(2+)]i), hormone secretion and cell viability, in a series of 85 pituitary samples...
November 2016: Journal of Endocrinology
https://www.readbyqxmd.com/read/27537539/pasireotide-for-the-prevention-of-pancreatic-fistula-following-pancreaticoduodenectomy-a-cost-effectiveness-analysis
#17
Nik Goyert, Gareth Eeson, Daniel J Kagedan, Ramy Behman, Madeline Lemke, Julie Hallet, Nicole Mittmann, Calvin Law, Paul J Karanicolas, Natalie G Coburn
OBJECTIVE: To determine the cost-effectiveness of perioperative administration of pasireotide for reduction of pancreatic fistula (PF). SUMMARY: PF is a major complication following pancreaticoduodenectomy (PD), associated with significant morbidity and healthcare-related costs. Pasireotide is a novel multireceptor ligand somatostatin analogue, which has been demonstrated to reduce the incidence of PF following pancreas resection; however, the drug cost is significant...
January 2017: Annals of Surgery
https://www.readbyqxmd.com/read/27537101/from-bulk-to-plasmonic-nanoparticle-surfaces-the-behavior-of-two-potent-therapeutic-peptides-octreotide-and-pasireotide
#18
Belén Hernández, Eduardo López-Tobar, Santiago Sanchez-Cortes, Yves-Marie Coïc, Bruno Baron, Alexandre Chenal, Sergei G Kruglik, Fernando Pflüger, Régis Cohen, Mahmoud Ghomi
Octreotide and pasireotide are two cyclic somatostatin analogues with an important clinical use in the treatment and diagnosis of neuroendocrine tumors. Herein, by the combined use of several techniques (UV-visible absorption, fluorescence, circular dichroism, ζ-potential, transmission electron microscopy, Raman scattering, surface-enhanced Raman scattering, and quantum mechanical calculations) we have followed the structural dynamics of these analogues in the bulk, as well as their binding sites on plasmonic (gold and silver) colloids...
September 21, 2016: Physical Chemistry Chemical Physics: PCCP
https://www.readbyqxmd.com/read/27473537/management-of-hyperglycemia-in-patients-with-acromegaly-treated-with-pasireotide-lar
#19
Susan L Samson
Pasireotide (Signifor(®)) long-acting release (LAR) is a next-generation somatostatin receptor ligand (SRL) approved for treatment of patients with acromegaly who have had an inadequate response to surgery or for whom surgery is not an option. Pasireotide LAR has been shown to be more effective than other SRLs in providing biochemical control in patients with acromegaly. However, hyperglycemia-related adverse events were more frequent in patients treated with pasireotide LAR than in those treated with other SRLs...
September 2016: Drugs
https://www.readbyqxmd.com/read/27429029/the-cost-of-postoperative-pancreatic-fistula-versus-the-cost-of-pasireotide-results-from-a-prospective-randomized-trial
#20
Linda W Ma, Ismael Dominguez-Rosado, Renee L Gennarelli, Peter B Bach, Mithat Gonen, Michael I D'Angelica, Ronald P DeMatteo, T Peter Kingham, Murray F Brennan, William R Jarnagin, Peter J Allen
OBJECTIVE: The objective of this study was to determine the costs of clinically significant postoperative pancreatic fistula (POPF) and to evaluate the cost-effectiveness of routine pasireotide use. SUMMARY OF BACKGROUND DATA: We recently completed a prospective randomized trial that demonstrated an 11.7% absolute risk reduction of clinically significant POPF with use of perioperative pasireotide in patients undergoing pancreaticoduodenectomy or distal pancreatectomy [POPF: pasireotide (n = 152), 9% vs placebo (n = 148), 21%; P = 0...
January 2017: Annals of Surgery
keyword
keyword
22928
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"